Program Leaders:
John Wagner, M.D.
Daniel Weisdorf, M.D.

Through basic research in stem cell biology and immunology, members of the Transplant Biology and Therapy Program work together to discover new stem cell transplantation therapies and treatments for cancers relating to the blood and bone marrow. This program represents the research arm of the University of Minnesota's world-famous Blood and Marrow Transplant (BMT) Program.

Research Areas

• Immunotherapy
• Stem cell biology
• Umbilical cord blood transplantation
• Unrelated donor transplantation

Researchers in the Transplant Biology and Therapy program work closely with the Masonic Cancer Center's Immunology Research Program members to further knowledge of using blood and marrow transplantation for treating cancer and other diseases. This groundbreaking research has led to the development of treatments for leukemia, lymphoma, and breast cancer.

Patient care is provided by the University of Minnesota Medical Center, Fairview Blood and Marrow Transplantation Program. The physicians who provide the patient care in this program are the same people who conduct research in the Transplant Biology and Therapy Research Program.

Program News

Daniel Weisdorf, M.D., Transplant Biology and Therapy Program co-leader, is featured in a YouTube video about academic medicine and clinical trials that is currently accessible on the University of Minnesota's Academic Health Center website.

U's Masonic Cancer Center receives $26 million to lead national blood and bone marrow cancer research
Findings will benefit thousands of patients diagnosed worldwide with leukemia, other cancers and disorders.
Transplant Biology and Therapy Program members Philip McGlave, M.D., and Jeffrey Miller, M.D., have received renewed five-year program project research grants totaling almost $26 million from the National Cancer Institute (NCI). Read more.